The compounding pharmacy lawsuit landscape has exploded since 2026, featuring a constellation of litigation involving manufacturers, regulators, and pharmacies fighting over the legality and exclusivity of compounded GLP-1 drugs like tirzepatide and semaglutide. Multiple cases have emerged simultaneously: Strive Compounding Pharmacy filed a landmark antitrust lawsuit on January 14, 2026, against Eli Lilly and Novo Nordisk in federal court in Texas, while major manufacturers are pursuing their own enforcement actions against compounding operations, and the FDA is battling compounding pharmacies in court over inspection authority. These overlapping lawsuits reflect a larger collision between the $13+ billion weight-loss drug market, the regulatory framework that governs compounding, and competition concerns that have reached the courtroom. Unlike traditional product liability cases, compounding pharmacy litigation centers on patent infringement, antitrust violations, trademark misuse, and regulatory authority—making it a complex legal battleground where no single case will resolve the entire industry conflict. A consumer might see these lawsuits as distant pharmaceutical corporate disputes, but they directly affect medication availability, cost, and safety for millions of people using compounded GLP-1 products.
The stakes are enormous. Compounding pharmacies have captured a significant share of the GLP-1 market by offering lower-cost alternatives to brand-name drugs. Manufacturers argue this threatens quality, safety, and intellectual property rights. Regulators claim compounding pharmacies are operating beyond their legal scope. Meanwhile, compounding pharmacies contend they’re being illegally suppressed through exclusionary contracts and aggressive enforcement. Understanding what’s actually happening in these lawsuits is critical for anyone considering compounded GLP-1 products or following the prescription drug market.
Table of Contents
- What Are the Antitrust Claims Against Eli Lilly and Novo Nordisk?
- The Manufacturer Enforcement Campaign Against Compounders
- The FDA’s Dual Approach—Regulatory Restrictions and Lawsuits
- Why Are Compounding Pharmacies Suing the FDA?
- Patent Disputes and Intellectual Property Conflicts
- The Role of Telehealth Companies in Compounding Litigation
- The Future of Compounding Pharmacy Litigation
- Conclusion
What Are the Antitrust Claims Against Eli Lilly and Novo Nordisk?
Strive Compounding Pharmacy’s January 2026 antitrust lawsuit alleges that Eli Lilly and Novo Nordisk engaged in exclusionary conduct specifically designed to suppress the market for compounded GLP-1 products. According to the complaint, these manufacturers signed exclusive agreements with telehealth companies, restricting those platforms from offering or recommending compounded alternatives to brand-name medications. This strategy, Strive argues, uses market power in the legitimate drug market to unfairly exclude competition in the compounding space. The lawsuit was filed in the U.S. District Court for the Western District of Texas, and it represents the first major antitrust challenge against manufacturers for allegedly using contractual arrangements to lock competitors out of distribution channels.
Antitrust law generally prohibits companies from using legitimate market power in one market to foreclose competition in another. Strive’s legal theory is that by controlling which medications telehealth platforms can offer—essentially locking compounding alternatives off the digital shelf—Eli Lilly and Novo Nordisk are illegally maintaining their monopoly pricing. The case is significant because it tests whether pharmaceutical manufacturers can legally restrict distribution channels to exclude compounded competitors. If Strive prevails, it could force major changes to how telehealth companies operate and which medications they’re permitted to offer patients. The defendants’ position, though not yet formally adjudicated, generally centers on intellectual property protection and regulatory compliance—they argue they’re protecting their patented drugs and ensuring quality, not engaging in exclusionary conduct. The outcome of this antitrust case will likely determine whether compounding pharmacies have legal recourse against similar exclusive arrangements in the future.
The Manufacturer Enforcement Campaign Against Compounders
Eli Lilly and Novo Nordisk haven’t just used contracts to limit competition; they’ve filed direct lawsuits against compounding pharmacies and the telehealth platforms selling their products. Eli Lilly sued Empower pharmacy, a Houston-based compounding operation, alleging unauthorized compounding and marketing of tirzepatide-based drugs in violation of the Lanham Act and the New Jersey Consumer Fraud Act. Lilly’s complaint centers on the claim that Empower used marketing materials and language that improperly referenced Lilly’s clinical research, misleading consumers into thinking the compounded product was equivalent to the brand-name version. A motion to dismiss was filed in October 2025, and as of April 2026, no trial date had been set—a clear sign that these cases are likely to involve years of litigation. Meanwhile, Novo Nordisk filed its own patent infringement lawsuit against Hims & Hers on February 9, 2026, targeting a telehealth company that had become a major distributor of compounded GLP-1 products.
This case represents a shift in enforcement strategy: rather than suing only the compounding pharmacy, manufacturers are now going after the platforms that market and sell these products to consumers. The limitation here is important: patent law protects specific formulations and delivery methods, and Novo’s case will turn on technical questions about whether compounded semaglutide actually infringes Novo’s patents or whether compounding falls into a different legal category. A critical weakness in the manufacturers’ strategy is that compounding pharmacies operate under state pharmacy law and have long been permitted to prepare medications based on prescriptions—they’re not manufacturing new drugs; they’re preparing existing active ingredients in different strengths or forms. The $21 million settlement between a compounding pharmacy and a private equity firm owner, reached to resolve False Claims Act allegations, signals that not all compounders are equally positioned to fight these battles. Smaller pharmacies lack the resources to mount expensive defenses, making settlements attractive even when the legal merits might be questionable. This creates a tiered system where well-funded compounders can litigate while smaller operations are forced to settle or exit the market.
The FDA’s Dual Approach—Regulatory Restrictions and Lawsuits
The FDA has launched a two-pronged campaign against large-scale compounding of GLP-1 products. On February 6, 2026, the agency announced it would restrict GLP-1 active pharmaceutical ingredients in non-FDA-approved compounded products and combat misleading direct-to-consumer advertising. This wasn’t merely a guidance document or warning letter—it represented a formal enforcement pivot. However, the FDA faces its own legal challenges: ten compounding pharmacies filed a lawsuit against the agency alleging unlawful inspections of state-regulated pharmacies. A court ruled that this case will proceed despite the FDA’s request to dismiss it, meaning a federal judge is now evaluating whether the FDA exceeded its authority when inspecting compounding operations. This litigation against the FDA is fundamentally important because it tests the boundaries of regulatory power. Compounding pharmacies operate under state pharmacy boards’ supervision, and there’s a genuine legal question about the extent to which the FDA—a federal agency—can inspect and enforce against them.
The court’s decision to allow the case to proceed suggests the judge found the compounding pharmacies’ arguments about unlawful regulatory overreach credible enough to warrant a trial. The limitation of the FDA’s position is that it must balance public safety concerns with legitimate questions about federalism and regulatory jurisdiction. The agency has legitimate concerns about quality control in large-scale compounding operations, but its enforcement tactics may not survive judicial scrutiny. The FDA’s February 2026 restrictions on GLP-1 active ingredients specifically target large-scale compounding—not pharmacists preparing medications for individual patients with valid prescriptions. This distinction matters legally and practically, because it suggests the FDA is trying to regulate the scale and scope of compounding rather than prohibit it entirely. The agency’s argument is that large-scale operations function like manufacturers and should be subject to FDA approval processes. Compounders counter that state pharmacy law explicitly permits compounding without FDA approval.
Why Are Compounding Pharmacies Suing the FDA?
The core complaint from ten compounding pharmacies is that the FDA conducted inspections of state-regulated pharmacies without legal authority to do so. Under state pharmacy law, compounding pharmacies are licensed and overseen by state boards, not the FDA. The federal agency traditionally doesn’t inspect retail pharmacies unless they’re manufacturing drugs at large scale or in ways that suggest they’re acting as manufacturers rather than compounders. The compounding pharmacies argue the FDA’s recent inspection campaign is an illegal overreach designed to suppress competition with brand-name drugs rather than a legitimate safety action. A comparison helps clarify the stakes: when your local pharmacy prepares a customized compounded medication based on a doctor’s prescription, the state pharmacy board oversees that operation. The FDA doesn’t typically get involved because the pharmacist isn’t manufacturing a new drug—they’re preparing an existing ingredient.
But when a compounding pharmacy operates at large scale, preparing thousands of doses weekly, the legal picture becomes murkier. The FDA argues that’s manufacturing and requires approval. Compounders argue it’s still compounding, just with higher volume, and remains within their state-sanctioned scope. The court’s decision to let the lawsuit proceed suggests the judge found this distinction legally meaningful. The practical tradeoff is significant: aggressive FDA enforcement might reduce access to affordable compounded GLP-1 products in the short term but could also address legitimate quality concerns in less-regulated operations. Conversely, limiting FDA authority might preserve access but could allow genuinely unsafe or low-quality compounding to continue undetected. Neither absolute outcome is ideal, which is why the litigation will likely produce a middle ground where the FDA can inspect for egregious safety violations but cannot simply shut down compounding operations based on scale alone.
Patent Disputes and Intellectual Property Conflicts
Patent law adds another layer to compounding pharmacy litigation. Novo Nordisk’s lawsuit against Hims & Hers raises the question of whether compounded semaglutide infringes the company’s patents. This isn’t straightforward. The active ingredient semaglutide itself may be patented, and the delivery mechanism or formulation might be patented as well. However, compounding pharmacies argue they’re preparing an established pharmaceutical ingredient in different strengths or delivery forms, which has historically been permitted under pharmacy law. A warning here is important: the assumption that “generic” or compounded versions are automatically legal is incorrect. Patent law doesn’t care whether you’re a brand-name manufacturer or a compounding pharmacy—if you’re making a patented invention without authorization, you’re potentially infringing.
However, compounding pharmacies have a longstanding legal defense based on the nature of their business. They argue they’re not manufacturing a patented product; they’re compounding an ingredient based on a valid prescription. This distinction—between manufacturing for the mass market versus compounding for an individual patient with a prescription—has never been clearly resolved in the GLP-1 context, making Novo’s lawsuit potentially precedent-setting. The limitation of manufacturer patent suits is that they assume compounding is sufficiently similar to manufacturing to trigger patent liability. But state pharmacy law and the Pharmacy Compounding Act of 1997 established a distinct regulatory category for compounding. If courts decide that compounding genuinely falls outside the scope of patent enforcement (a legally arguable position), then Novo and other manufacturers will find their patent protection ineffective against compounders. This could explain why manufacturers are also pursuing antitrust claims and FDA enforcement—patents alone may not be sufficient to stop compounding.
The Role of Telehealth Companies in Compounding Litigation
Telehealth platforms like Hims & Hers and Ro have become central targets in compounding pharmacy litigation because they control the distribution channel between compounders and consumers. When Novo Nordisk sued Hims & Hers for patent infringement, and when Eli Lilly’s exclusive agreements restrict telehealth partners from offering compounded alternatives, these platforms become the real battleground. Telehealth companies have been caught in the crossfire: manufacturers pressure them to stop offering compounded products, while compounders depend on them for market access.
The Strive antitrust lawsuit specifically alleges that exclusive agreements between manufacturers and telehealth companies are designed to lock compounders out of distribution. If Strive prevails, telehealth companies could be freed from these restrictions and able to offer compounded alternatives without fear of breach-of-contract liability. This would reshape the competitive landscape for GLP-1 products and likely increase consumer access to lower-cost compounded options. Conversely, if manufacturers successfully defend their exclusive agreements as legitimate business practices, compounding access through telehealth will remain restricted regardless of what happens in other litigation.
The Future of Compounding Pharmacy Litigation
The compounding pharmacy lawsuits of 2026 are setting precedents that will affect pharmaceutical competition for years. Three major questions remain unresolved: First, can manufacturers legally suppress compounding through exclusive agreements (Strive’s antitrust claim)? Second, can the FDA enforce against state-regulated compounding pharmacies over their objections (the FDA lawsuit)? Third, do patent laws apply to compounded products the same way they apply to manufactured drugs (Novo’s case against Hims & Hers)? The answers to these questions will determine whether compounded GLP-1 products remain a viable competitive alternative or become legally and commercially inaccessible. The trajectory suggests increased litigation and regulatory pressure in the near term, with potential for larger systemic resolution through legislative action.
Congress could clarify the scope of FDA authority over compounding, modify patent law to explicitly address compounding pharmacies, or impose different rules for novel uses of established ingredients. The current legal ambiguity creates inefficiency, uncertainty, and incentives for aggressive litigation. A clearer statutory framework would likely reduce the number of cases while settling the underlying policy questions that courts are currently trying to resolve through traditional litigation.
Conclusion
Compounding pharmacy lawsuits represent a collision between three powerful forces: intellectual property rights, regulatory authority, and market competition. Multiple cases are underway simultaneously—Strive’s antitrust challenge, manufacturer enforcement actions, FDA regulatory battles, and patent disputes—and they’re unlikely to be resolved quickly or comprehensively.
Consumers, patients, and healthcare providers need to understand that the availability and cost of compounded GLP-1 products may shift significantly as litigation progresses. If you use or are considering compounded GLP-1 products, monitor ongoing developments in these cases, consult with a healthcare provider about the safety and efficacy of compounded versus brand-name options, and be aware that legal and regulatory changes could affect availability. For those following the pharmaceutical industry or securities litigation, compounding pharmacy lawsuits are indicators of broader tensions over drug pricing, regulatory scope, and patent policy that extend far beyond GLP-1 products.